The GIFT Nifty futures, which is an early indicator of the Nifty50 index, was trading 0.08% lower by 22 points at 25,984.50, indicating that the domestic benchmark indices are likely to make a negative start on Tuesday. 

On Monday, 30 September, Domestic benchmark indices S&P BSE Sensex crashed 1,272.07 points or 1.49% to end at 84,299.78 while the Nifty50 traded 368.10 points lower or 1.41% and settled at 25,810.85.

Here are some stocks that are likely to remain in focus on 1 October.

NTPC: The company’s subsidiary, NTPC Green Energy has announced signing a Memorandum of Understanding (MoU) with the Government of Rajasthan for developing 25 gigawatt (GW) of renewable energy projects in Rajasthan.

Tata Power: The company has signed a MoU with the Rajasthan Government to invest Rs 1.2 lakh crore in renewable energy projects. The plan includes initiatives in transmission, distribution, manufacturing, rooftop installations, nuclear power, and EV charging infrastructure. 

Aurobindo Pharma: The USFDA has issued 10 procedural observations for its API facility in Telangana, following an inspection. The company aims to address these observations promptly. 

Mankind Pharma: The company has successfully completed the transfer of its Over the Counter business to its subsidiary, Mankind Consumer Products Private Ltd, as a going concern on a slump sale basis. 

Jindal Stainless: The company has partnered with CJ Darci Logistics Ltd to manufacture lightweight, sustainable stainless steel containers. As a part of this partnership, the company has supplied 2.2 metric tonnes of JT stainless steel for each container. 

India Glycols: The company has announced expanding its capacity to its existing grain-based distillery in Kashipur, Uttrakhand, by adding an additional 100 kilolitres per day (KLPD) to its existing capacity. The company has also increased the capacity at its bio-fuel ethanol plant at the same location by 180 KLDP. 

Blue Dart: The company has announced a general price hike that will be effective from 1 January 2025, with an average price hike ranging from 9% to 12%. However, the company stated that the customers who sign up between 1 October and 31 December 2024 will not be affected by the price hike. 

Dr Reddy’s Laboratories: The company has completed the acquisition of Haleon plc’s global consumer healthcare brands in the nicotine replacement therapy sector for a total consideration of GBP 458 million.

Unichem Labs: The company has announced signing an asset purchase agreement with Bayshore Pharmaceuticals, USA. As a part of the agreement, Bayshore will sell its product approvals and all goodwill related to 9 US ANDAs (abbreviated new drug applications) and will also sell its generic formulating marketing and distribution business in the US. 

Feeling overwhelmed by the markets? Let Unicorn Signals be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!